Literature DB >> 15725089

Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.

L M Griffith1, J P McCoy, C D Bolan, D F Stroncek, A C Pickett, G F Linton, A Lundqvist, R Srinivasan, S F Leitman, R W Childs.   

Abstract

Delayed donor erythropoiesis and pure red-cell aplasia (PRCA) complicate major-ABO mismatched non-myeloablative allogeneic stem-cell transplantation. To characterize these events, we analysed red-cell serology and chimaerism in lymphohaematopoietic lineages, including plasma cells and B cells, in 12 consecutive major-ABO incompatible transplants following cyclophosphamide/fludarabine-based conditioning. Donor erythropoiesis was delayed to more than 100 days in nine (75%) patients including six (50%) who developed PRCA. During PRCA, all patients had persistent anti-donor isohaemagglutinins and recipient plasma cells (5-42%), while myeloid and T cells were completely donor in origin. In contrast, B-cell chimaerism was frequently full-donor when significant anti-donor isohaemagglutinins persisted. Four patients with early mixed haematopoietic chimaerism and the prolonged presence of anti-donor isohaemagglutinins and recipient plasma cells developed delayed-onset (>100 days post-transplant) red cell transfusion dependence and PRCA after myeloid chimaerism converted from mixed to full donor. These findings confirm that donor-erythropoiesis is impacted by temporal disparities in donor immune-mediated eradication of recipient lymphohaematopoietic cells during major-ABO incompatibility and suggest that plasma cells are relatively resistant to graft-versus-host haematopoietic effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15725089     DOI: 10.1111/j.1365-2141.2005.05364.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  29 in total

Review 1.  An outcome-based review of an accredited Specialist in Blood Banking (SBB) program: 25 years and counting.

Authors:  Karen M Byrne; Traci D Paige; Willy A Flegel
Journal:  Immunohematology       Date:  2020-01

2.  Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia.

Authors:  Akane Kunitomi; Takayuki Ishikawa; Kenichirou Tajima; Yoshiteru Konaka; Masato Yagita
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

3.  Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Authors:  Michael Scordo; Meier Hsu; Ann A Jakubowski; Gunjan L Shah; Christina Cho; Molly A Maloy; Scott T Avecilla; Esperanza B Papadopoulos; Boglarka Gyurkocza; Hugo Castro-Malaspina; Roni Tamari; Richard J O'Reilly; Miguel-Angel Perales; Sergio A Giralt; Brian C Shaffer
Journal:  Biol Blood Marrow Transplant       Date:  2019-01-06       Impact factor: 5.742

4.  Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.

Authors:  Ross M Fasano; Ewelina Mamcarz; Sharon Adams; Theresa Donohue Jerussi; Kyoko Sugimoto; Xin Tian; Willy A Flegel; Richard W Childs
Journal:  Br J Haematol       Date:  2014-04-18       Impact factor: 6.998

5.  Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.

Authors:  Fleur M Aung; Benjamin Lichtiger; Gabriela Rondon; C Cameron Yin; Amin Alousi; Sairah Ahmed; Borje S Andersson; Qaiser Bashir; Stefan O Ciurea; Chitra Hosing; Roy Jones; Partow Kebriaei; Issa Khouri; Yago Nieto; Betul Oran; Simrit Parmar; Muzaffar Qazilbash; Nina Shah; Elizabeth J Shpall; Richard E Champlin; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-26       Impact factor: 5.742

6.  Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation.

Authors:  F Khan; M A Linden; N D Zantek; G M Vercellotti
Journal:  Transfus Med       Date:  2014-05-09       Impact factor: 2.019

7.  Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.

Authors:  Matthew M Hsieh; Elizabeth M Kang; Courtney D Fitzhugh; M Beth Link; Charles D Bolan; Roger Kurlander; Richard W Childs; Griffin P Rodgers; Jonathan D Powell; John F Tisdale
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

8.  Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins.

Authors:  Georg Stussi; Jörg Halter; Eveline Bucheli; Piero V Valli; Lutz Seebach; Jürg Gmür; Alois Gratwohl; Urs Schanz; Jakob R Passweg; Jörg D Seebach
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

Review 9.  B cells and transplantation: an educational resource.

Authors:  Trudy N Small; William H Robinson; David B Miklos
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

10.  Serum IgM levels independently predict immune response to influenza vaccine in long-term survivors vaccinated at >1 year after undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Yusuke Fukatsu; Yasuyuki Nagata; Miwa Adachi; Tomohiro Yagyu; Takaaki Ono
Journal:  Int J Hematol       Date:  2016-12-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.